• Skip to main content
  • Skip to secondary menu
  • Skip to primary sidebar
  • Skip to secondary sidebar
  • Skip to footer

  • COVID-19
  • Opinion
  • Health IT
    • Behavioral Health
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Patient Engagement
    • Population Health Management
    • Revenue Cycle Management
    • Social Determinants of Health
  • Digital Health
    • Artificial Intelligence
    • Blockchain
    • Mobile Health
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • M&A
  • Value-based Care
    • Accountable Care (ACOs)
    • Medicare Advantage
  • Life Sciences
  • Research

Guardant Health Nabs $100M for Biopsy-Free Cancer Genomic Testing

by HITC Staff 01/08/2016 Leave a Comment

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

Guardant Health

Guardant Health, a Redwood City, CA-based company revolutionizing cancer detection through biopsy-free tumor sequencing has raised $100M in Series D funding led by healthcare-investment firm OrbiMed. Existing Guardant Health investors Khosla Ventures, Sequoia Capital, Lightspeed Venture Partners, Pejman Mar, Formation 8, Heritage Group, and others also participated in the funding round.

Founded in 2012 by a team of serial entrepreneurs with expertise in next-generation sequencing, single-cell genomics and cancer diagnostics, Guardant Health will utilize the funding to accelerate their reach of its biopsy-free sequencing platform for cancer, Guardant360®.  Guardant360 helps physicians identify genomic alterations in patients with advanced cancers, without the cost, risk, or pain of invasive biopsies. The 70-gene blood test is used in advanced cancer patients with visceral solid tumor cancers or metastases, and interrogates all four types of genomic alterations.

GuardantHealth

The test is used to prevent repeat invasive biopsies when cancer has progressed or recurred despite treatment, or when an initial biopsy is unobtainable or has insufficient tissue. It is the only ctDNA test that includes all guideline-recommended somatic genomic targets in a single test. Unlike hotspot tests, Guardant360 sequences complete exons so as not to miss uncommon or rare mutations. Based on the tumor genomic profile, clinicians receive a report of actionable genomic alterations and a list of FDA-approved treatments and clinical trials for which the patient could be eligible.

Guardant Health will also use the funds to further expand its Digital Sequencing™ platform into new product lines that address the complete cancer-care continuum.

“Genomic technologies are on the cusp of fundamentally changing cancer care. As new targeted cancer therapies emerge, our platform becomes that much more powerful. Oncologists already recognize our value; increasingly, investors do as well. This new funding is a strong vote of confidence in our technology, science, commercial, and reimbursement operations from one of the most sophisticated healthcare investors in the world. We will use it to help as many patients as we can to proactively combat cancer,” said Helmy Eltoukhy, Guardant Health CEO in a statement.  

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

Tagged With: Cancer Detection, Genomic Testing, Guardant Health, Oncology

Get in-depth healthcare technology analysis and commentary delivered straight to your email weekly

Reader Interactions

Primary Sidebar

Subscribe to HIT Consultant

Latest insightful articles delivered straight to your inbox weekly.

Submit a Tip or Pitch

Knowledge Hub

 How Top Health Plans Use AI to Save Money and Work Smarter How Top Health Plans Use AI to Save Money and Work Smarter

 How to Build Hybrid Care Models Around Remote Patient Monitoring How to Build Hybrid Care Models Around Remote Patient Monitoring

Trending

Metriport Launches Open-Source API to Instantly Pull Medical Records from Any EHR

Metriport Launches Open-Source API to Instantly Pull Medical Records from Any EHR

Nearly Half Of Consumers Report Their Healing has Been Directly Impacted by Difficulty Paying Medical Bills

Consumers Cite Healthcare Affordability as Biggest Concern to Paying Medical Bills

Mayo Clinic, GE HealthCare, Partner on Medical Imaging and Theranostics Innovation

Roundups: 16 Recent Strategic Digital Health Partnerships

How Telehealth Can Combat Clinician Burnout

How Telehealth Can Combat Clinician Burnout

Q/A: DocStation CEO Shares How AI Will Help Pharmacies Use the DIR Fee Changes to Their Advantage

Q/A: DocStation CEO Shares How AI Will Help Pharmacies Use the DIR Fee Changes to Their Advantage

Debunking Myths About Virtual Care to Drive Health Equity

Debunking 3 Myths About Virtual Care to Drive Health Equity

Provider AI Strategy Moves From The IT Dept. To The C-Suite

Notable Launches ChatGPT-Like Assistant for Patients

Notable Launches ChatGPT-Like Assistant for Patients

Intermountain to Replace Cerner with Epic Enterprise EHR by 2025

Intermountain to Replace Cerner with Epic Enterprise EHR by 2025

M&A: PE Firm Acquires NextGen Healthcare EHR for $1.8B

M&A: NextGen Healthcare EHR Acquired by PE Firm for $1.8B

Secondary Sidebar

Footer

Company

  • About Us
  • Advertise with Us
  • Reprints and Permissions
  • 2023 Editorial Calendar
  • Submit An Op-Ed
  • Contact
  • Subscribe

Editorial Coverage

  • Opinion
  • Health IT
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Population Health Management
    • Revenue Cycle Management
  • Digital Health
    • Artificial Intelligence
    • Blockchain Tech
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • Value-Based Care
    • Accountable Care
    • Medicare Advantage

Connect

Subscribe to HIT Consultant Media

Latest insightful articles delivered straight to your inbox weekly

Copyright © 2023. HIT Consultant Media. All Rights Reserved. Privacy Policy |